Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $4.80.

Several research analysts recently weighed in on the stock. Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI opened at $0.77 on Tuesday. The company has a market cap of $95.38 million, a PE ratio of -0.60 and a beta of 0.20. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.95. The firm’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $1.05.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The firm had revenue of $42.79 million during the quarter, compared to analysts’ expectations of $36.07 million. As a group, equities research analysts anticipate that Karyopharm Therapeutics will post -0.93 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Large investors have recently bought and sold shares of the business. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $31,000. Cubist Systematic Strategies LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $494,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $143,000. AQR Capital Management LLC grew its stake in shares of Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after purchasing an additional 622,194 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $167,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).